{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=5", "query": { "condition": "Leukemia, Myelogenous, Acute", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 2504, "total_pages": 251, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T12:27:22.451Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02909972", "title": "Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "ALRN-6924", "type": "DRUG" }, { "name": "ALRN-6924 in combination with cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aileron Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2016-09", "completion_date": "2019-08", "has_results": false, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 6, "location_summary": "Denver, Colorado • Tampa, Florida • The Bronx, New York + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "The Bronx", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02909972" }, { "nct_id": "NCT00990054", "title": "Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2009-12", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2015-03-24", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 8, "location_summary": "Duarte, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00990054" }, { "nct_id": "NCT02152956", "title": "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AML" ], "interventions": [ { "name": "Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2014-06-09", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 20, "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152956" }, { "nct_id": "NCT07356154", "title": "A Study of Revumenib and Mezigdomide in People With Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Acute Leukemia", "Relapse Leukemia", "Refractory Leukemia", "Refractory Acute Leukemia", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Revumenib", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 52, "start_date": "2026-01-16", "completion_date": "2029-01-16", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 10, "location_summary": "Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07356154" }, { "nct_id": "NCT00004105", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "estramustine phosphate sodium", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004105" }, { "nct_id": "NCT00822094", "title": "Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" }, { "name": "Intensive Salvage Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 126, "start_date": "2009-02", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 31, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00822094" }, { "nct_id": "NCT02343939", "title": "Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Entospletinib", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2015-07-01", "completion_date": "2019-02-21", "has_results": true, "last_update_posted_date": "2019-11-15", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 14, "location_summary": "Los Angeles, California • Chicago, Illinois • Maywood, Illinois + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343939" }, { "nct_id": "NCT00806325", "title": "Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sepsis", "Acute Myeloid Leukemia" ], "interventions": [], "intervention_types": [], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2007-11", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806325" }, { "nct_id": "NCT03050216", "title": "QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "ALT-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2017-05-16", "completion_date": "2019-12-15", "has_results": true, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050216" }, { "nct_id": "NCT07566585", "title": "Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML - Acute Myeloid Leukemia", "AML With Mutated NPM1", "AML, Adult Recurrent" ], "interventions": [ { "name": "SOC+BSB-2002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BlueSphere Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2026-04-21", "completion_date": "2026-09-08", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-09T12:27:22.451Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07566585" } ] }